The activated form of STAT5 drives miR-155 expression, which in turn promotes proliferation of malignant T cells [27] indicating that miR-155 plays an oncomiR function in CTCL. The gene discussed is STAT5B; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.